FDA Product Code OZN: C. Difficile Toxin Gene Amplification Assay
Clostridioides difficile is the leading cause of healthcare-associated infectious diarrhea. FDA product code OZN covers C. difficile toxin gene amplification assays for rapid molecular diagnosis.
These PCR-based assays detect toxin gene sequences — tcdA and/or tcdB — directly from stool specimens, providing same-day results for CDI diagnosis with sensitivity superior to toxin immunoassays and speed superior to toxigenic culture.
OZN devices are Class II medical devices, regulated under 21 CFR 866.3130 and reviewed by the FDA Microbiology panel.
Leading manufacturers include Roche Molecular Systems, Inc., Quidel Corporation and Cepheid.
FDA 510(k) Cleared C. Difficile Toxin Gene Amplification Assay Devices (Product Code OZN)
About Product Code OZN - Regulatory Context
510(k) Submission Activity
18 total 510(k) submissions under product code OZN since 2012, with 18 receiving FDA clearance (average review time: 106 days).
Submission volume has increased in recent years - 2 submissions in the last 24 months compared to 1 in the prior period - suggesting growing market activity in this device classification.
FDA 510(k) Review Time - OZN Product Code
Recent submissions under OZN have taken an average of 160 days to reach a decision - up from 100 days historically. Manufacturers should account for longer review timelines in current project planning.
OZN devices are reviewed by the Microbiology panel. Browse all Microbiology devices →